Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance

Crispr Therapeutics AGTrade
iShares 7-10 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while iShares 7-10 Year Treasury Bond ETF trades at $92.89. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

CRSPIEF
Market Cap
$5.23B
Sector
Health
52-Week High
$76.78$97.99
52-Week Low
$44.34$92.76
Enterprise Value
$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.

Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.

iShares 7-10 Year Treasury Bond ETF

IEF (iShares 7-10 Year Treasury Bond ETF) trades at $92.96 with a modest 0.22% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent institutional activity includes Bank of America increasing its position by 69.8% in Q2 2026. The ETF continues regular dividend distributions, with the latest payment of $0.32 per share in early August 2026.

The outlook for IEF remains challenged by rising Treasury yields and inflation concerns, with technical weakness suggesting continued pressure. However, institutional accumulation and consistent dividend payments provide some support. Key risks include Federal Reserve rate policy uncertainty and Middle East geopolitical tensions impacting oil prices and inflation expectations.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About iShares 7-10 Year Treasury Bond ETF

The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.

Read more on IEF